PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Rosemont acquires Lucis Pharma to boost portfolio

The company will gain access to a considerable pipeline of liquid products covering various disease areas.

Rosemont Pharmaceuticals has announced the acquisition of Lucis Pharma. The purchased company is a specialist pharmaceutical business based in the UK.

Consequently, Rosemont has expanded its existing portfolio and will gain access to a considerable pipeline of products, offering therapies across the UK and within overseas markets.

Lucis – which was founded in 2012 – has become a notable provider in the development and licensing of novel treatments. Meanwhile, with several products covering a wide variety of conditions, Lucis has built a robust portfolio, particularly serving the patient’s need for liquid medicines.

The acquisition will also allow Rosemont to widen its portfolio and enter the unit dose or sachet markets through emerging products while growing its business through significant Lucis product launches during 2021/22.

Howard Taylor, chief executive officer at Rosemont, reflects on the acquisition: “As well as continuing to broaden our portfolio and add to our strong growth globally, this acquisition also gives access to pipeline products and developer relationships to accelerate our entry into new product areas such as sachets.”

He added: “We will continue creating innovative solutions that meet the needs of dysphagic patients and establish best practices for their care”.

Rosemont has half a century of experience providing novel, prescription, oral liquid solutions for patients with swallowing difficulties, across a range of therapeutic areas. These include cardiac health, endocrinology and pain management.

Currently, Rosemont supplies 27 international markets, including North America, South America, the Middle East, Africa, Asia, Oceania and countries in Europe.

At its production facility in Leeds, the company manufactures in excess of one million litres of bulk liquid. This equates to four million bottles of liquid medicines every year.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026